FEATURES


Viewpoints

Researchers Identify Mechanism by Which NSAIDs Prevent Colon Cancer

Researchers Identify Mechanism by Which NSAIDs Prevent Colon Cancer

NSAIDs target stem cells that have accumulated mutations that could lead to cancer development and a biochemical pathway that leads to apoptosis.

Post-Operative Recovery of Gastric Motility in the Geriatric Patient

Post-Operative Recovery of Gastric Motility in the Geriatric Patient

Many changes occur in the gastrointestinal tract during the aging process that can directly impact gastric motility following surgery.

Feature Articles

Presenteeism May Be a Problem for Oncologists and, Ultimately, Their Patients

Presenteeism May Be a Problem for Oncologists and, Ultimately, Their Patients

Research highlights how lack of guidelines regarding illness and adequate staffing at hospitals may be reason for oncologists working while sick.

Evaluating Benign Thyroid Nodules: The Appropriate Time Interval After Initial Fine Needle Aspiration

Evaluating Benign Thyroid Nodules: The Appropriate Time Interval After Initial Fine Needle Aspiration

Kenneth D. Burman, MD, discusses study suggesting that optimal time for repeat evaluation of benign thyroid nodules is 2 to 4 years.

Mining Cancer-Specific Disease Comorbidities from a Large Observational Health Database

Mining Cancer-Specific Disease Comorbidities from a Large Observational Health Database

[Cancer Informatics] When examined, cancer comorbidities can reveal valuable clues to understanding the underlying genetic mechanisms of cancers. The comorbidity patterns among different patient groups and the effect of age and gender on cancer comorbidity patterns are investigated.

Slideshows

ZYDELIG® (idelalisib) for Relapsed Follicular B-cell Non-Hodgkin Lymphoma (FL)

ZYDELIG® (idelalisib) for Relapsed Follicular B-cell Non-Hodgkin Lymphoma (FL)

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed follicular non-Hodgkin lymphoma (FL).

Table of Contents

Slide 3: Indication, Dosage, ...

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

ZYDELIG® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia

This slideshow reviews drug information for ZYDELIG® (idelalisib), indicated for relapsed chronic lymphoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide ...

From the Advisory Board

Treatment Deintensification for HPV-Associated Oropharynx Cancer

Treatment Deintensification for HPV-Associated Oropharynx Cancer

The Eastern Cooperative Oncology Group (ECOG) conducted a trial to investigate whether treatment deintensification was feasible in patients with HPV-associated cancer.

CME

Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation

Ponatinib Active in Patients with CML and Ph+ ALL Resistant/Intolerant to Dasatinib or Nilotinib or Who Have the T315I Mutation

This CME activity from ASCO 2012 reviews the results of the ongoing PACE (Ponatinib Ph+ ALL and CML Evaluation) trial.

Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

Crizotinib Provides Clinically Meaningful Antitumor Activity in Patients with Previously Treated ALK-Positive Advanced Non-Small-Cell Lung Cancer

This CME activity from ASCO 2012 reviews crizotinib in patients with ALK-positive non-small cell lung cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs